129042-57-5

Usage

Uses

Used in Pharmaceutical Research:
DL-3-Amino-3-(2-naphthyl)propionic acid is used as a reagent in pharmaceutical research for its potential to contribute to the synthesis of new pharmaceuticals. Its unique structure allows for the development of compounds with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, DL-3-Amino-3-(2-naphthyl)propionic acid is used as a precursor for the production of various organic compounds. Its versatile chemical structure facilitates the creation of a range of molecules with different applications.
Used in Medicinal Chemistry:
DL-3-Amino-3-(2-naphthyl)propionic acid is utilized in medicinal chemistry for its potential pharmacological properties. Its structural features may enable the design of new drugs with specific therapeutic targets.
Used in Drug Development:
In drug development, DL-3-Amino-3-(2-naphthyl)propionic acid may be employed as a starting material for the creation of novel drug candidates. Its unique backbone and functional groups offer opportunities for the discovery of new therapeutic agents.

InChI:InChI=1/C13H13NO2/c14-12(8-13(15)16)11-6-5-9-3-1-2-4-10(9)7-11/h1-7,12H,8,14H2,(H,15,16)

Upstream product

• 51557-26-7 3-(2-naphthyl)acrylic acid 
• 141-82-2 malonic acid 
• 66-99-9 β-naphthaldehyde 

Downstream Products

• 403600-04-4 (R,S)-ethyl 3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3-(naphthalen-2-yl)propanoate 
• 268542-15-0 C₁₈H₂₁NO₄ 
• 767282-94-0 (R)-3-amino-3-(2-naphthyl)propanoic acid 
• 167887-15-2 3-(1,3-dioxoisoindolin-2-yl)-3-(naphthalen-2-yl)propanoic acid 

Relevant academic research and scientific papers

Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase

In the last two decades, trans-sialidase of Trypanosoma cruzi (TcTS) has been an important pharmacological target for developing new anti-Chagas agents. In a continuous effort to discover new potential TcTS inhibitors, 3-amino-3-arylpropionic acid derivatives (series A) and novel phthaloyl derivatives (series B, C and D) were synthesized and molecular docking, TcTS enzyme inhibition and determination of trypanocidal activity were carried out. From four series obtained, compound D-11 had the highest binding affinity value (?11.1 kcal/mol) compared to reference DANA (?7.8 kcal/mol), a natural ligand for TS enzyme. Furthermore, the 3D and 2D interactions analysis of compound D-11 showed a hydrogen bond, π-π stacking, π-anion, hydrophobic and Van der Waals forces with all important amino acid residues (Arg35, Arg245, Arg314, Tyr119, Trp312, Tyr342, Glu230 and Asp59) on the active site of TcTS. Additionally, D-11 showed the highest TcTS enzyme inhibition (86.9% ± 5) by high-performance ion exchange chromatography (HPAEC). Finally, D-11 showed better trypanocidal activity than the reference drugs nifurtimox and benznidazole with an equal % lysis (63 ± 4 and 65 ± 2 at 10 μg/mL) and LC50 value (52.70 ± 2.70 μM and 46.19 ± 2.36 μM) on NINOA and INC-5 strains, respectively. Therefore, D-11 is a small-molecule with potent TcTS inhibition and a strong trypanocidal effect that could help in the development of new anti-Chagas agents.

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

Novel malonamide derivatives as αvβ3 antagonists. Syntheses and evaluation of 3-(3-indolin-1-yl-3-oxopropanoyl)aminopropanoic acids on vitronectin interaction with αvβ3

In attempt to find novel integrin of αvβ3 antagonists, we selected SC65811 and its guanidine analogue (1) as lead compounds. Modification of the glycine part of SC65811 led to a new series of malonamide derivatives that exhibited αvβ3 inhibitory activity. Among them, (R,S)-3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3- (pyridin-3-yl)propanoic acid (43a) showed not only potent activity with an IC50 value of 3.0 nM but also good selectivity for αvβ3 relative to αIIbβ3, α5β1, and αvβ5 with IC50 values of 19000, 11000, and 14 nM, respectively. Furthermore, optimization of 43a led to the most potent αvβ3 antagonist, (R,S)-3-(3-{6-[(4,5-dihydro-1H-imidazol-2-yl)aminoindolin-1-yl}- 3-oxopropanoylamino)-3-(quinolin-3-yl)propanoic acid (431) with an IC50 value of 0.42 nM. The synthesis and the structure-activity relationships of these malonamide derivatives are presented.

META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.

Substituted aryl ureas as high potency sweeteners

Substituted ureas and thioureas are disclosed for use as high potency sweeteners.